Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and synthesis of novel angular 4,5-pyranocoumarin fluorescent probes for detecting hydrazine and their applications.

RSC advances·2025
Same author

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.

Future oncology (London, England)·2025
Same author

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

JAMA·2025
Same author

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

ACMGA: a reference-free multiple-genome alignment pipeline for plant species.

BMC genomics·2024
Same author

A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.

Future oncology (London, England)·2024

Related Experiment Video

Updated: May 17, 2026

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

A Bayesian approach for PK/PD modeling with PD data below limit of quantification.

Huafeng Zhou1, Alan Hartford, Kuenhi Tsai

  • 1Agensys, Inc., Santa Monica, California, USA. hzhou@agensys.com

Journal of Biopharmaceutical Statistics
|October 19, 2012
PubMed
Summary

This study introduces a Bayesian method for analyzing pharmacodynamic (PD) data below the limit of quantification (BLOQ) in pharmacokinetic/pharmacodynamic (PK/PD) models. The Bayesian approach, implemented using Markov-chain Monte Carlo, outperforms traditional methods for BLOQ data analysis.

More Related Videos

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins
09:40

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Published on: June 11, 2015

Related Experiment Videos

Last Updated: May 17, 2026

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins
09:40

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Published on: June 11, 2015

Area of Science:

  • Pharmacometrics
  • Statistical Modeling
  • Pharmacodynamics

Background:

  • Pharmacokinetic/pharmacodynamic (PK/PD) models are crucial for drug development.
  • Handling data below the limit of quantification (BLOQ) presents a significant challenge in PK/PD modeling.
  • Existing methods for BLOQ data often lack statistical rigor.

Purpose of the Study:

  • To describe and evaluate a Bayesian approach for modeling BLOQ pharmacodynamic (PD) data within PK/PD frameworks.
  • To compare the performance of the proposed Bayesian method against common ad hoc approaches.
  • To provide practical guidance for implementing the Bayesian method in real-world PK/PD analyses.

Main Methods:

  • Implementation of a Bayesian framework using the inhibitory sigmoid Emax model.
  • Utilizing Markov-chain Monte Carlo (MCMC) simulation via WinBUGS software.
  • Conducting a simulation study to assess the Bayesian approach's performance against data imputation (½LOQ) and data omission.

Main Results:

  • The Bayesian approach demonstrated superior performance compared to replacing BLOQ data with ½LOQ or ignoring BLOQ data.
  • Simulation results support the efficacy of the proposed Bayesian method.
  • A case study confirmed the practical applicability of the Bayesian approach for real PK/PD data.

Conclusions:

  • The Bayesian approach offers a robust and statistically sound method for handling BLOQ PD data in PK/PD modeling.
  • This method should be considered a valuable complementary tool for analyzing BLOQ data in drug development.
  • The study provides a practical framework for applying Bayesian techniques to challenging PK/PD datasets.